Myriad Genetics (0K3W) Share Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0K3W Analyst Ratings

Moderate Sell

0 Buy

4 Hold

3 Sell

Based on 7 analysts giving stock ratings to

Myriad

Genetics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0K3W Stock 12 Month Forecast

Average Price Target

$2.95

▼(-7.81% Downside)

Based on 7 Wall Street analysts offering 12 month price targets for Myriad Genetics in the last 3 months. The average price target is $2.95 with a high forecast of $4.00 and a low forecast of $2.00. The average price target represents a -7.81% change from the last price of $3.20.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","3":"$3","5":"$5","7":"$7","9":"$9"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.9499999999999997,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.95</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3,5,7,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.04,3.1138461538461537,3.187692307692308,3.2615384615384615,3.3353846153846156,3.4092307692307693,3.483076923076923,3.556923076923077,3.6307692307692307,3.7046153846153844,3.7784615384615385,3.852307692307692,3.926153846153846,{"y":4,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.04,3.0330769230769232,3.026153846153846,3.019230769230769,3.0123076923076924,3.005384615384615,2.9984615384615383,2.9915384615384615,2.9846153846153847,2.9776923076923074,2.9707692307692306,2.963846153846154,2.9569230769230765,{"y":2.9499999999999997,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.04,2.96,2.88,2.8,2.72,2.64,2.56,2.48,2.4,2.3200000000000003,2.24,2.16,2.08,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.531,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.539,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.05,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.115,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.158,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.63,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.02,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.61,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.05,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.295,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.885,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1785542400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.04,"date":1788220800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$4.00

Average Price Target$2.95

Lowest Price Target$2.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Westenberg

Piper Sandler

$8.5→$2

Sell

-37.50%

Downside

Downgraded

09/01/26

Analyst Cuts Myriad Genetics to Sell, Slashes Price Target to $2 Amid Structural Profitability Concerns

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$2.5

Sell

-21.88%

Downside

Reiterated

08/21/26

Jefferies Sticks to Their Sell Rating for Myriad Genetics (MYGN)

Mason Carrico

Stephens

Hold

-6.25%

Downside

Assigned

08/18/26

Myriad Genetics price target lowered to $3 from $5 at StephensMyriad Genetics price target lowered to $3 from $5 at Stephens

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

08/03/26

Myriad Genetics (MYGN) Gets a Hold from Guggenheim

Michael Ryskin

Bank of America Securities

$4→$3.2

Sell

0.00%

Upside

Reiterated

08/03/26

Bank of America Securities Remains a Sell on Myriad Genetics (MYGN)

Brandon Couillard

Wells Fargo

$5.5→$3

Hold

-6.25%

Downside

Reiterated

08/02/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: AptarGroup (NYSE: ATR), Myriad Genetics (NASDAQ: MYGN) and HCA Healthcare (NYSE: HCA)

Kyle Boucher

TD Cowen

$6→$4

Hold

25.00%

Upside

Assigned

07/31/26

Myriad Genetics: Q2 Miss, Guidance Cut Lead to Lower $4 Price Target and Maintained Hold Rating

William Bonello

Craig-Hallum

$10

Buy

212.50%

Upside

Assigned

05/06/26

Analysts Offer Insights on Healthcare Companies: Myriad Genetics (NASDAQ: MYGN) and Dianthus Therapeutics (NASDAQ: DNTH)

Lu Li

UBS

$8→$6

Hold

87.50%

Upside

Reiterated

02/25/26

Myriad Genetics price target lowered to $6 from $8 at UBSMyriad Genetics price target lowered to $6 from $8 at UBS

Andrew Cooper

Raymond James

$6.53→$8

Buy

150.00%

Upside

Reiterated

01/13/26

Raymond James Remains a Buy on Myriad Genetics (MYGN)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Westenberg

Piper Sandler

$8.5→$2

Sell

-37.50%

Downside

Downgraded

09/01/26

Analyst Cuts Myriad Genetics to Sell, Slashes Price Target to $2 Amid Structural Profitability Concerns

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$2.5

Sell

-21.88%

Downside

Reiterated

08/21/26

Jefferies Sticks to Their Sell Rating for Myriad Genetics (MYGN)

Mason Carrico

Stephens

Hold

-6.25%

Downside

Assigned

08/18/26

Myriad Genetics price target lowered to $3 from $5 at StephensMyriad Genetics price target lowered to $3 from $5 at Stephens

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

08/03/26

Myriad Genetics (MYGN) Gets a Hold from Guggenheim

Michael Ryskin

Bank of America Securities

$4→$3.2

Sell

0.00%

Upside

Reiterated

08/03/26

Bank of America Securities Remains a Sell on Myriad Genetics (MYGN)

Brandon Couillard

Wells Fargo

$5.5→$3

Hold

-6.25%

Downside

Reiterated

08/02/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: AptarGroup (NYSE: ATR), Myriad Genetics (NASDAQ: MYGN) and HCA Healthcare (NYSE: HCA)

Kyle Boucher

TD Cowen

$6→$4

Hold

25.00%

Upside

Assigned

07/31/26

Myriad Genetics: Q2 Miss, Guidance Cut Lead to Lower $4 Price Target and Maintained Hold Rating

William Bonello

Craig-Hallum

$10

Buy

212.50%

Upside

Assigned

05/06/26

Analysts Offer Insights on Healthcare Companies: Myriad Genetics (NASDAQ: MYGN) and Dianthus Therapeutics (NASDAQ: DNTH)

Lu Li

UBS

$8→$6

Hold

87.50%

Upside

Reiterated

02/25/26

Myriad Genetics price target lowered to $6 from $8 at UBSMyriad Genetics price target lowered to $6 from $8 at UBS

Andrew Cooper

Raymond James

$6.53→$8

Buy

150.00%

Upside

Reiterated

01/13/26

Raymond James Remains a Buy on Myriad Genetics (MYGN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

PTGXProtagonist Therapeutics

AXGNAxoGen

ATECAlphatec Holdings

CABACabaletta Bio

ONCBeOne Medicines

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Myriad Genetics

3 Months

Michael RyskinBank of America Securities

Success Rate

9/11 ratings generated profit

Average Return

+25.70%

Copying Michael Ryskin's trades and holding each position for 3 Months would result in 81.82% of your transactions generating a profit, with an average return of +25.70% per trade.

1 Year

Michael RyskinBank of America Securities

Success Rate

10/11 ratings generated profit

Average Return

+38.30%

Copying Michael Ryskin's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +38.30% per trade.

2 Years

Michael RyskinBank of America Securities

Success Rate

10/11 ratings generated profit

Average Return

+49.71%

Copying Michael Ryskin's trades and holding each position for 2 Years would result in 90.91% of your transactions generating a profit, with an average return of +49.71% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0K3W Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0K3W has received 1 Buy Ratings, 6 Hold Ratings, and 4 Sell Ratings. 0K3W average Analyst price target in the past 3 months is 2.95.

Each month's total comprises the sum of three months' worth of ratings.

0K3W Financial Forecast

0K3W Earnings Forecast

Next quarter’s earnings estimate for 0K3W is -$0.21 with a range of -$0.28 to -$0.15. The previous quarter’s EPS was -$0.25. 0K3W beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0K3W has Performed in-line its overall industry.

0K3W Sales Forecast

Next quarter’s sales forecast for 0K3W is $191.32M with a range of $188.60M to $192.30M. The previous quarter’s sales results were $190.70M. 0K3W beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0K3W has Performed in-line its overall industry.

0K3W Stock Forecast FAQ

What is GB:0K3W’s average 12-month price target, according to analysts?

Based on analyst ratings, Myriad Genetics’s 12-month average price target is 2.95.

What is GB:0K3W’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for GB:0K3W, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Myriad Genetics a Buy, Sell or Hold?

Myriad Genetics has a consensus rating of Moderate Sell, which is based on 0 buy ratings, 4 hold ratings and 3 sell ratings.

What is Myriad Genetics’s share price target?

The average share price target for Myriad Genetics is 2.95. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $4.00 ,and the lowest forecast is $2.00. The average share price target represents -7.81% Decrease from the current price of $3.2.

What do analysts say about Myriad Genetics?

Myriad Genetics’s analyst rating consensus is a Moderate Sell. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of Myriad Genetics?

To buy shares of GB:0K3W, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Myriad Genetics (0K3W) Share Forecast & Price Target

0K3W Analyst Ratings

0K3W Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Myriad Genetics

0K3W Analyst Recommendation Trends

0K3W Financial Forecast

0K3W Earnings Forecast

0K3W Sales Forecast

0K3W Stock Forecast FAQ

Detailed List of Analyst Forecasts